Document is current
Any future updates will be listed below
-
Authors
Bali, Divya
Hansson, Oskar
Janelidze, Shorena
-
Funding
Funding for this research was provided by:
Alzheimer’s Association (SG-23-1061717)
Swedish Research Council (2022-00775)
ERA PerMed (ERAPERMED2021-184)
The Knut and Alice Wallenberg foundation (2017-0383)
The Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University
The Swedish Alzheimer Foundation (AF-980907)
The Swedish Brain Foundation (FO2021-0293)
The Parkinson foundation of Sweden (1412/22)
The Cure Alzheimer’s fund
The Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
The Skåne University Hospital Foundation (2020-O000028)
Regionalt Forskningsstöd (2022-1259)
The Swedish federal government under the ALF agreement (2022-Projekt0080)
Lund University
- License Information
-
More Information
Article History
Received: 24 August 2023
Accepted: 14 January 2024
First Online: 8 February 2024
Declarations
:
: The study was executed in agreement with the Ethics Committee at Lund University, Sweden. All study participants have signed an informed consent form in order to participate in the study.
: Figure InternalRef removed is original and was created using BioRender.com.
: OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens.
